Analysis of the scope of indications and clinical application effects of Pazopanib (Victor)

1. Drug Overview and Mechanism of Action

Pazopanib (trade name Votrient®) is an oral small molecule multi-target tyrosine kinase inhibitor (TKI), which mainly acts on angiogenesis-related VEGFR1-3, PDGFR-α/β and c-KIT signaling pathways. By inhibiting these receptor kinases, pazopanib can effectively block tumor angiogenesis and reduce tumor blood supply, while directly inhibiting tumor cell proliferation and promoting apoptosis. This dual mechanism enables it to exhibit significant anti-tumor activity in advanced solid tumors, especially in renal clear cell carcinoma (RCC) and soft tissue sarcoma (STS).

2. Scope of indications

According to the approval information of FDA and EMA , the main indications of pazopanib include:

1.Advanced or metastatic renal clear cell carcinoma (RCC): used for patients who are new to treatment or have previously received cytokine therapy. RCC is the most common renal malignancy in adults, in which advanced patients often have lower survival rates. The launch of pazopanib provides this group with a new oral targeted therapy option.

2.Advanced soft tissue sarcoma (STS): It is especially suitable for patients with non-liposarcoma subtypes who have failed previous chemotherapy. There are many types of soft tissue sarcoma, and some types have limited response to traditional chemotherapy. The multi-target effect of pazopanib provides a new treatment strategy for refractory patients.

In addition, pazopanib has also been explored in some clinical studies for use in other solid tumors, such as thyroid cancer, hepatocellular carcinoma and gynecological tumors. However, the main approvals are still focused on RCC and STS.

3. Clinical application effects

In clinical studies in advanced clear cell renal cell carcinoma, VEG110727 and COMPARZ Trials have shown that pazopanib monotherapy can significantly prolong the progression-free survival (PFS) of patients. The median PFS is approximately 8-9 months, and the overall survival (OS) is approximately OS 28-30 months. Compared with sorafenib, pazopanib has similar efficacy and has better tolerability and quality of life scores. In particular, pazopanib is slightly lower than sorafenib in terms of side effects such as fatigue and hand-foot syndrome.

In the field of soft tissue sarcoma, the PALETTE study shows that for patients with advanced STS who have failed previous chemotherapy, pazopanib treatment can significantly prolong progression-free survival, with a median PFS of 4.6 months, some patients achieved partial remission (PR). This efficacy has important clinical significance in refractory soft tissue sarcoma and provides a new treatment option for long-term tumor control.

The anti-tumor effect of pazopanib is not only reflected in the extension of survival, but also in the disease control rate (DCR). Studies have shown that the disease control rate of RCC patients can reach 70%-80% and that of STS patients is also between 50%-60% . This means that most patients’ tumors can be effectively controlled or partially relieved after using pazopanib, thereby delaying disease progression and improving quality of life.

4. Precautions for clinical use and comprehensive evaluation

As an oral targeted drug, the safety of pazopanib is relatively controllable, but some common side effects still need to be paid attention to, including: hypertension, liver function damage, diarrhea, fatigue, hand-foot syndrome, and thyroid dysfunction. Clinically, patients should regularly monitor blood pressure, liver function and blood routine before medication and during treatment, and adjust the dose in a timely manner according to adverse reactions.

Overall, pazopanib has played an important clinical role in advanced renal clear cell carcinoma and soft tissue sarcoma , which can both prolong patient survival and improve quality of life. In the treatment of advanced solid tumors, pazopanib's multi-target mechanism provides new treatment options for refractory patients and occupies an important position in individualized treatment plans. With the deepening of more clinical studies, pazopanib may have wider application value in other solid tumors in the future.

Reference link:https://www.drugs.com